Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 7;8(5):e1028.
doi: 10.1212/NXI.0000000000001028. Print 2021 Jul.

Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals

Affiliations

Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals

Takayuki Fujii et al. Neurol Neuroimmunol Neuroinflamm. .

Abstract

Objectives: To assess the prevalence of antiplexin D1 antibodies (plexin D1-immunoglobulin G [IgG]) in small fiber neuropathy (SFN) and the effects of these antibodies in vivo.

Methods: We developed an ELISA for plexin D1-IgG using a recombinant extracellular domain of human plexin D1 containing the major epitope and sera from 58 subjects previously studied with a standard tissue-based indirect immunofluorescence assay (TBA). We screened 63 patients with probable SFN and 55 healthy controls (HCs) for serum plexin D1-IgG using ELISA. The results were confirmed by TBA. IgG from 3 plexin D1-IgG-positive patients, 2 plexin D1-IgG-negative inflammatory disease controls, and 2 HCs was intrathecally injected into mice, which were assessed for mechanical and thermal hypersensitivity 24 and 48 hours after injection.

Results: The ELISA had 75% sensitivity and 100% specificity using the TBA as a standard, and the coincidence rate of ELISA to TBA was 96.6% (56/58). The frequency of plexin D1-IgG was higher in patients with SFN than in HCs (12.7% [8/63] vs 0.0% [0/55], p = 0.007). Purified IgG from all 3 plexin D1-IgG-positive patients, but not 2 plexin D1-IgG-negative patients, induced significant mechanical and/or thermal hypersensitivity compared with IgG from HCs. In mice injected with plexin D1-IgG-positive but not D1-IgG-negative patient IgG, phosphorylated extracellular signal-regulated protein kinase immunoreactivity, an activation marker, was confined to small dorsal root ganglion neurons and was significantly more abundant than in mice injected with HC IgG.

Conclusions: Plexin D1-IgG is pathogenic but with low prevalence and is a potential biomarker for immunotherapy in SFN.

PubMed Disclaimer

Figures

Figure 1
Figure 1. ELISA Screen and Confirmatory TBA for Plexin D1-IgG
(A) Indirect ELISA for plexin D1-IgG in a previous cohort of 8 patients with NeP with plexin D1-IgG and 50 non-NeP patients (30 disease controls and 20 HCs) previously determined by TBA. Disease controls included 6 with amyotrophic lateral sclerosis; 4 each with multiple system atrophy, systemic lupus erythematosus, and neuro-Behçet disease; 3 with hereditary spinocerebellar degeneration; 2 each with Parkinson disease, normal pressure hydrocephalus, and Sjögren syndrome; and 1 each with Alzheimer disease, dementia with Lewy bodies, and corticobasal degeneration. The difference in OD values between plexin D1-coated wells and D1-uncoated wells (corrected OD value) was calculated, and the test was considered “ELISA-positive” when the corrected OD value was above the mean + 5 SD of the 50 plexin D1-IgG-negative controls determined by TBA (0.163, dotted line). Six of 8 patients with NeP with plexin D1-IgG by TBA were positive for plexin D1-IgG by ELISA, whereas all 50 disease controls and HCs without plexin D1-IgG by TBA were negative for plexin D1-IgG by ELISA. (B) Comparison of the newly established ELISA with TBA for plexin D1-IgG. The overall coincidence rate of ELISA to TBA was 96.6% (56/58). (C) Indirect ELISA for plexin D1-IgG in the present SFN cohort. The difference in OD values between plexin D1-coated wells and D1-uncoated wells (corrected OD value) was calculated, and the test was considered “ELISA-positive” when the corrected OD value was above 0.163 (dotted line). Plexin D1-IgG was positive in 8 of 63 (12.7%) of all patients with SFN, including 6 of 38 (15.8%) patients with iSFN, 2 of 25 (8.0%) patients with sSFN, and 2 of 55 (3.6%) HCs by ELISA. (D) IgG (green) from a representative patient with SFN (iSFN Case 1 in table 2) showed positive immunostaining of mouse small DRG neurons, whereas there was no significant immunoreactivity in 2 ELISA-seropositive HCs (HC 1 and HC 2). Nuclei are counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (E) Correlation between the corrected OD value and the disease duration in patients with SFN with plexin D1-IgG (n = 8). There was a significant positive correlation between them (Spearman rank correlation; rs = 0.9639, p = 0.0001). Even after 1 outlier with the highest optical density was removed, the correlation between the corrected OD value and the disease duration remained significant (rs = 0.982, p < 0.0001). HC = healthy control; IgG = immunoglobulin G; iSFN = idiopathic small fiber neuropathy; OD = optical density; SFN = small fiber neuropathy; sSFN = secondary small fiber neuropathy; TBA = tissue-based indirect immunofluorescence assay.
Figure 2
Figure 2. Assessment of Pain-Like Behaviors and Neuronal Activation in Passive Transfer Mice 24 Hours After Injection
(A) Mechanical pain hypersensitivity was assessed by calibrated von Frey filaments (0.04, 0.07, 0.16, 0.40, and 0.60 g) 24 hours after injection. Mice treated with purified IgG from patients 1, 2, and 3 showed significantly higher reaction rates to each stimulation strength (0.07, 0.16, 0.40, and 0.60 g filaments) than HC IgG-treated mice (1-way ANOVA with Dunnett test; *p < 0.01). No significant differences in reaction rates were seen with IgG from 2 inflammatory disease controls (1 patient with NBD and 1 patient with NPSLE) and patients 1, 2, and 3 after preadsorption with rhPlexin D1 compared with control IgG (1-way ANOVA with Dunnett test). (B) Indirect IFA of mouse L5 DRG sections revealed that IgG (green) from the patient with SFN (patient 3) with plexin D1-IgG but not control IgG bound to small DRG neurons. IgG from patient 3 preabsorbed with rhPlexin D1 (2 µg/mL) showed no significant immunoreactivity to mouse DRG. Nuclei are counterstained with 4′,6-diamidino-2-phenylindole (blue). Immunostaining of pERK, a marker of primary afferent neuron activation, in L5 DRG of mice treated with purified IgG from patient 3 and control 24 hours after injection. Most of the pERK-labeled neurons in mice treated with purified IgG from patient 3 are small DRG neurons (≤25 µm in diameter). Few neurons are labeled for pERK in mice treated with control IgG and IgG from patient 3 after preabsorption with rhPlexin D1. Sections were counterstained with hematoxylin. (C) Distribution of pERK immunoreactivity among different-sized neurons was analyzed. DRG neurons were stratified as small (≤25 mm in diameter) and large (>25 mm in diameter) neurons. The pERK-labeled neurons in L5 DRG of mice treated with purified IgG from patients 1, 2, and 3 were predominantly small neurons of less than 25 μm in diameter. Scale bars = 50 µm and (inset) = 25 µm. ANOVA = analysis of variance; DRG = dorsal root ganglia; HC = healthy control; IFA = immunofluorescence assay; IgG = immunoglobulin G; NBD = neuro-Behçet disease; NPSLE = neuropsychiatric systemic lupus erythematosus; pERK = phosphorylated extracellular signal-regulated protein kinase; Pre-Ab = preabsorbed; rhPlexin D1 = recombinant human plexin D1.

Similar articles

Cited by

References

    1. Terkelsen AJ, Karlsson P, Lauria G, et al. . The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol. 2017;16(11):934-944. - PubMed
    1. Oaklander AL, Nolano M. Scientific advances in and clinical approaches to small-fiber polyneuropathy: a review. JAMA Neurol. 2019;76(10):1240-1251. 10.1001/jamaneurol.2019.2917. - DOI - PMC - PubMed
    1. Sopacua M, Hoeijmakers JGJ, Merkies ISJ, et al. . Small-fiber neuropathy: expanding the clinical pain universe. J Peripher Nerv Syst. 2019;24(1):19-33. - PubMed
    1. de Greef BTA, Hoeijmakers JGJ, Gorissen-Brouwers CML, et al. . Associated conditions in small fiber neuropathy—a large cohort study and review of the literature. Eur J Neurol. 2018;25(2):348-355. - PMC - PubMed
    1. Peters MJ, Bakkers M, Merkies IS, et al. . Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands. Neurology. 2013;81(15):1356-1360. 10.1212/WNL.0b013e3182a8236e. - DOI - PubMed

Publication types